GENERAL INFORMATION

1. Title of Dataset: COVID-19 Vaccine Manufacturing Agreements 

2. Author Information
	A. Principal Investigator Contact Information
		Name: Suerie Moon
		Institution: Global Health Centre, Graduate Institute of International and Development Studies
		Address: Chemin Eugène-Rigot 2A, Case postale 1672, 1211 Geneva 1, Switzerland
		Email: suerie.moon@graduateinstitute.ch

	B. Associates or Co-investigators Contact Information
                Name: Surabhi Agarwal, Gurgen Tadevosyan, Adrián Alonso Ruiz, Anna Bezruki (former collaborator)
                Institution: Global Health Centre, Graduate Institute of International and Development Studies
                Address: Chemin Eugène-Rigot 2A, Case postale 1672, 1211 Geneva 1, Switzerland
                Email: globalhealthresearch@graduateinstitute.ch  

3. Date of data collection (single date, range, approximate date): approximate range, 2020-07-01-present


4. Information about funding sources that supported the collection of the data: Swiss National Science Foundation


SHARING/ACCESS INFORMATION

1. Licenses/restrictions placed on the data: Open Access, Creative Commons and distributed in accordance with the Creative Commons Attribution Non Commercial International (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. Third party material are not included. See: https://creativecommons.org/licenses/by-nc/4.0/ 


2. Recommended citation for this dataset: Global Health Centre. (2021). COVID-19 Vaccine Manufacturing Agreements. Graduate Institute of International and Development Studies. Retrieved from: https://www.knowledgeportalia.org/covid19-vaccine-manufacturing 


DATA & FILE OVERVIEW

1. Data are updated once every month. 


METHODOLOGICAL INFORMATION

1. Description of methods used for collection/generation of data: 
Information on arrangements aggregated from publicly available sources, including news reports (links in dataset). Country population and income information available from the World Bank (www.data.worldbank.org), with exception of Taiwanese data, which is available from the Taiwanese government (www.eng.stat.gov.tw). 


DATA-SPECIFIC INFORMATION FOR: [COVID-19_Vaccine_Agreements]

1. Variable List: 

Sheet 3: Manufacturing Arrangements. This sheet contains information on manufacturing arrangements made between vaccine developers and manufacturers.

Vaccine developer: Company name from each vaccine candidate.

Developer Location: Main location/headquarters of each vaccine developer.

Income Level: Income level of the country where the vaccine developer is located.

Manufacturer: Manufacturer name.

Manufacturer Type: Defined as Privately Held, Publicly-Traded, State-Owned Enterprise, Government Agency, Public-private partnership, or Unclear. 

Manufacturer Location: Main location/headquarters of the manufacturer 

Income Level2: Income level as defined by the World Bank.

Anticipated Production Dose/Year (in millions): The estimated anticipated number of vaccine doses to be produced per year (in millions).

Anticipated Production Total Doses (in millions): The estimated number of total vaccine doses to be produced as part of the arrangement (in millions).

Date Arrangement Publicly Announced: The date that the arrangement was publicly announced. When only the month of the arrangement is available, date is reported as the first of the month. 

Part of Combination Procurement Arrangement: Yes/No. Denotes whether the arrangement is part of a combination procurement arrangement captured in the Primary Procurement Arrangements sheet. 

Government Sponsored/Supported: Arrangements that were reached as a result of some form of government sponsorship or support (whether or not they are part of combination procurement arrangements) are reported here with the name of the relevant country. Blanks denote arrangements for which there is no indication of government sponsorship or support.

Arrangement Category: The type of manufacturing expected through the arrangement is grouped into the following categories: Bulk substance production, Fill-and-finish, Full process (encompassing both bulk substance production and fill-and-finish), Phased full process (denoting arrangements that will explicitly start with only one component of manufacturing production, such as fill-and-finish before eventually expanding to a full process), and Other. Arrangements where the precise nature of the arrangement is not clear are categorized by default as Full process.

Arrangement Details: Free text on publicly available details of the arrangement. 

Associated upgrades/technology transfer details: Free text on any information available regarding any upgrades or technology transfer that is anticipated to occur as part of the arrangement.

Financing details: Free text on any information available regarding the financing of the arrangement.

Primary Market Intended For: The primary market the resultant vaccine doses are intended to be available in. Categorized by country name, region (using World Bank regional definitions), World, or Unspecified.
Income Level3: Income level of the primary market, where available (i.e., for a country).

Secondary Market: The secondary market, if applicable, that the resultant vaccine doses are intended to be available in. Categorized by country name, region (using World Bank regional definitions), World, or Unspecified.

Income Level4: Income level of the secondary market, where available (i.e., for a country).

Notes: Free text tracking of relevant information on the arrangements.

Source: URLs for all sources used for each arrangement

4. Missing data codes: 
“Not available,” NA (as abbreviated form of Not Available), and blanks are used to signify data that is not available or not relevant.